• Nicotine Signaling and Chronic Kidney Disease Progression

  2026-10-07

  Jain and Jaimes integrate clinical observations with animal and mechanistic evidence to explain how nicotine may contribute to chronic kidney disease progression through non-neuronal nicotinic acetylcholine receptors, oxidative stress, and profibrotic signaling. The review’s main contribution is its careful connection of smoking-associated renal outcomes with nicotine biology while recognizing that nicotine is only one component of tobacco smoke and that causality remains incompletely resolved.

• Pollen Interference in Hazardous Aerosol Spectroscopy

  2026-10-07

  A 2024 Molecules study examined how pollen can distort excitation–emission matrix fluorescence classification of hazardous bioaerosol-related samples. By combining spectral transformations with random-forest classification, the authors reported 89.24% accuracy and clearer separation of several bacterial and toxin-related classes, while also identifying important limits for real-world deployment.

• Annexin V-FITC Apoptosis Kit: Interpreting Cell Death

  2026-10-06

  The Annexin V-FITC/PI Apoptosis Assay Kit can do more than classify dying cells: it can anchor a broader evidence framework for interpreting immunogenic cell death. This article connects phosphatidylserine externalization and membrane integrity with findings from recent colorectal cancer research while clarifying what the assay can—and cannot—prove.

• Recombinant Annexin V Purification: Study Insights

  2026-10-06

  Burger and colleagues reported a concise purification strategy for recombinant human annexin V intended for demanding biophysical analyses. The study’s central innovation was combining gentle bacterial-cell opening with calcium-dependent, reversible membrane association and a final ion-exchange separation, yielding protein judged highly pure by gel electrophoresis and HPLC profiling.

• Ro 3306: CDK1 Inhibition in Cell-Cycle Context

  2026-10-05

  Ro 3306 is a selective CDK1 inhibitor used to interpret mitotic entry, G2/M arrest, and DNA repair phenotypes. This article connects CDK1 perturbation with phase-specific mTORC1 signaling to clarify what synchronized-cell results can—and cannot—demonstrate.

• TP53 Mutation, FTH, and Ferroptosis in Glioblastoma

  2026-10-05

  A 2025 Neuroscience Bulletin study links TP53 mutation status to altered iron handling in glioblastoma models through an ITCH–FTH axis. The findings suggest that increased intracellular free iron may create a genotype-associated vulnerability to ferroptosis, although the evidence remains preclinical and requires validation in clinically representative GBM systems.

• DNase I (RNase-Free): Evidence, Scope and Limits

  2026-10-04

  A source-critical overview of DNase I (RNase-free), covering its stated cleavage principles, the meaning of an RNase-free designation, evidence quality, application boundaries, and why the supplied neuroscience study does not validate enzyme performance.

• Shufeng Xingbi Therapy in Allergic Rhinitis Rats

  2026-10-03

  A 2025 bioRxiv preprint examined how Shufeng Xingbi Therapy affects allergic rhinitis in rats through behavioral, nasal-tissue, immune, and gut-microbiota endpoints. The reported improvements are consistent with coordinated changes in allergic inflammation and intestinal metabolites, but the preprint design does not establish clinical efficacy or prove a causal microbiota mechanism.

• DNase I (RNase-free) for Reliable Assays

  2026-10-02

  Learn how DNase I (RNase-free), SKU K1088, can reduce DNA-related confounding in RNA extraction, RT-PCR, and in vitro transcription workflows supporting cell viability, proliferation, and cytotoxicity studies. This scenario-based guide connects enzyme mechanism, protocol controls, transcript-quality interpretation, and practical supplier selection.

• ML133 HCl: An Assay-First Guide to Kir2.1

  2026-10-01

  ML133 HCl is a selective potassium channel inhibitor for dissecting Kir2.1-dependent potassium ion transport. This assay-first guide connects its pH-sensitive pharmacology with pulmonary artery smooth muscle cell proliferation research, experimental controls, and the mechanistic findings of a peer-reviewed pulmonary hypertension study.

• METTL14–DHRS4-AS1 Axis in Ulcerative Colitis

  2026-10-01

  This study identifies METTL14-dependent m6A regulation of the lncRNA DHRS4-AS1 as a protective mechanism in ulcerative colitis. Its cell and mouse experiments connect METTL14 to the DHRS4-AS1/miR-206/A3AR axis, NF-κB activation, apoptosis, and inflammatory tissue injury, offering a mechanistic framework for studying RNA methylation in intestinal inflammation.

• Cyclic di-GMP: From Biofilms to STING

  2026-09-30

  Cyclic di-GMP is an intracellular second messenger linking bacterial persistence biology with STING-focused immune modulation research. This article translates the latest antitoxin findings into practical assay decisions while defining its responsible use in cancer immunotherapy studies.

• Fenofibrate, PPARα–YAP Signaling, and Liver Aging

  2026-09-30

  The reference study shows that fenofibrate-induced liver enlargement and activation of the PPARα–YAP axis are preserved across several aging mouse models. Its findings clarify how aging influences hepatic hypertrophy, proliferation, and signaling responses while providing a framework for interpreting liver growth in lipid metabolism research.

• Imatinib Hydrochloride: Assay Design Beyond IC50

  2026-09-29

  Imatinib hydrochloride is a benchmark multi-target kinase inhibitor, but its value in cancer research extends beyond a single IC50 measurement. This guide connects Abl, c-Kit, and PDGFR assay design with new conformational insights into kinase dephosphorylation and offers a practical workflow for interpreting biochemical and cellular data.

• Tomivosertib Suppresses Ectopic Activity in Human DRG

  2026-09-29

  The reference study tested MNK inhibition directly in cultured human dorsal root ganglion neurons obtained from patients with radiculopathy. Tomivosertib rapidly and reversibly reduced spontaneous activity, altered action-potential and afterhyperpolarization properties, and suppressed eIF4E Ser209 phosphorylation, providing human cellular evidence for MNK signaling as a potential neuropathic-pain target.

8144 records 1/543 page Next 12345 下5页 Last page